US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicines

84.90

0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

Loading ...

Overview Company News Filings

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Everest Medicines to Review Annual Results on March 25, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

TYK Medicines, Inc's (HKG:2410) largest shareholders are private companies who were rewarded as market cap surged HK$3.3b last week

Simply Wall St.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

TYK Medicines Concludes H-Share Full Circulation

MT Newswires Live

TYK Medicines Completes H Share Full Circulation

50 Years of Service: From Milkman's Son to Advancing Access to Medicines

ACCESS Newswire

3D Medicines Inc. Reports Resolution in Civil Proceedings, Ensures Continued Operations

Steven Cohen's Strategic Acquisition in Praxis Precision Medicines Inc

TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access to Life-Changing Medicines

Market Chatter: China Healthcare Regulator Defends Efficacy of Local Generic Medicines in Hospital System

MT Newswires Live

TYK Medicines Secures Hong Kong Exchange Listing Approval for Over 173.6 Million H Shares

MT Newswires Live

3D Medicines Appoints Chief Commercial Officer

MT Newswires Live

3D Medicines Inc. Appoints New Chief Commercial Officer

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

GSK PLC (GSK) Q4 2024 Earnings Call Highlights: Strong Specialty Medicines Drive Growth Amid ...

Cencora Q1 Earnings: Revenue And EPS Beat On Strong Push From Obesity Drugs, Specialty Medicines

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCO/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"01-03 16:00:00 EST","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514867732","title":"Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867732","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514867732?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:02","pubTimestamp":1740603720,"startTime":"0","endTime":"0","summary":"Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026. Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer. Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025. Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time. REDWOOD CITY, Calif., Feb. 26, 2025  -- Revolution Medicines, Inc. , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2024, and provided an update on corporate progress.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revolution-medicines-reports-fourth-quarter-210200565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ199S13.USD","BK4563","LU1720051017.SGD","NE","LU1854104046.USD","LU1548497426.USD","BK4092","MDCO","IE0002270589.USD","LU1861219969.SGD","BK4588","LU1978683503.SGD","LU2360107325.USD","PFS","LU2298322129.HKD","LU0124384867.USD","CI","LU1059921491.USD","RVMDW","IE00B19Z3581.USD","LU0289739699.SGD","BK4605","OS","IE00B19Z3B42.SGD","BK4585","LU1861214812.USD","LU1861215975.USD","QD","IE00BD6J9T35.USD","LU0868494617.USD","BK4196","BK4139","IE00B7SZLL34.SGD","BK4166","LU2065732104.USD","LU2357305700.SGD","RVMD","LU0724618433.USD","BK4195","LU1861220033.SGD","BK4512","LU1720051108.HKD","ON","BK4097","BK4211","BK4503","LU0058720904.USD","LU0348723411.USD","PRGS","LU1854103824.USD"],"gpt_icon":0},{"id":"2514169063","title":"Everest Medicines to Review Annual Results on March 25, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2514169063","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514169063?lang=en_us&edition=fundamental","pubTime":"2025-02-25 17:09","pubTimestamp":1740474562,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. ( ($HK:1952) ) has provided an update. Everest Medicines Ltd. has announced that its board of directors will meet on March 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-to-review-annual-results-on-march-25-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-to-review-annual-results-on-march-25-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2514706984","title":"Revolution Medicines to Participate in March 2025 Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514706984","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514706984?lang=en_us&edition=fundamental","pubTime":"2025-02-25 05:05","pubTimestamp":1740431100,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Feb.  24, 2025  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/24/3031527/0/en/Revolution-Medicines-to-Participate-in-March-2025-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4512","LU2357305700.SGD","BK4588","LU1861215975.USD","LU1861214812.USD","LU1720051108.HKD","BK4141","LU1978683503.SGD","LU2298322129.HKD","LU1861219969.SGD","LU1854103824.USD","LU0124384867.USD","RVMD","BK4585","ON","LU0348723411.USD","MDCO","BK4605","LU2360107325.USD","LU1854104046.USD","BK4139","LU0724618433.USD","IE00BD6J9T35.USD","IE00BZ199S13.USD","LU1861220033.SGD","LU1720051017.SGD","LU1548497426.USD"],"gpt_icon":0},{"id":"2513210957","title":"European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2513210957","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513210957?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries –。The EMA validation follows the announcement last week that the U.S. Food and Drug and Administration  accepted Gilead’s New Drug Applications  for lenacapavir for PrEP and will assess them under priority review.The EMA applications are supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead. In PURPOSE 1 , data showed twice-yearly lenacapavir demonstrated zero infections in the lenacapavir group and 100% risk reduction and superiority compared to background HIV incidence  for the investigational use of HIV prevention in cisgender women. In PURPOSE 2 , there were two HIV infections in the lenacapavir group, demonstrating 99.9% of participants in the lenacapavir group did not acquire HIV infection, a 96% risk reduction in HIV infections, and superiority compared to bHIV among a broad and geographically diverse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-validates-gilead-133000551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0058720904.USD","LU1571399168.USD","LU0320765992.SGD","BK4139","BK4578","BK4585","BK4583","LU1585245621.USD","LU0109394709.USD","BK4215","BK4156","LU0889565916.HKD","BK4550","GILD","LU0289739699.SGD","LU1430594728.SGD","LU1839511570.USD","IE0002270589.USD","MDCO","LU2089984988.USD","IE00B19Z3581.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","BK4087","LU1066051498.USD","BK4532","LU1066053197.SGD","LU2468319806.SGD","CHMP","BK4588","LU2087621335.USD","IE00BZ1G4Q59.USD","BK4566","IE00B19Z3B42.SGD","BK4568","MAA","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2513711489","title":"The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513711489","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513711489?lang=en_us&edition=fundamental","pubTime":"2025-02-24 16:01","pubTimestamp":1740384060,"startTime":"0","endTime":"0","summary":"TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent  and Adult Patients with HAE.1. The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients.In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1. ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda   announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO  for subcutaneous administration in adolescents  and adult patients with Hereditary Angioedema .1. The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce HAE burden and improving their Quality of Life.\"HAE affects an estimated 1 in 50,000 people worldwide","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/european-medicines-agency-ema-approved-080100583.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-ema-approved-080100583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLDYK493.USD","LU0205193047.USD","LU1169590202.USD","BK4007","BK4198","LU0205194284.USD","TAK","LU0012050646.USD","HAE","IE00B64QTZ34.USD","MDCO","LU0106261612.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2512462559","title":"TYK Medicines, Inc's (HKG:2410) largest shareholders are private companies who were rewarded as market cap surged HK$3.3b last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2512462559","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512462559?lang=en_us&edition=fundamental","pubTime":"2025-02-20 07:42","pubTimestamp":1740008534,"startTime":"0","endTime":"0","summary":"Key Insights TYK Medicines' significant private companies ownership suggests that the key decisions are influenced by...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2410/tyk-medicines-shares/news/tyk-medicines-incs-hkg2410-largest-shareholders-are-private","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","MDCO","02410"],"gpt_icon":0},{"id":"2512434915","title":"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512434915","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512434915?lang=en_us&edition=fundamental","pubTime":"2025-02-20 05:05","pubTimestamp":1739999100,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Feb.  19, 2025  (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-ad","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3029138/0/en/Revolution-Medicines-to-Report-Financial-Results-for-Fourth-Quarter-and-Full-Year-2024-After-Market-Close-on-February-26-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","LU2298322129.HKD","BK4605","BK4512","ON","LU2360107325.USD","LU0724618433.USD","LU0348723411.USD","LU1548497426.USD","LU2357305700.SGD","LU1720051017.SGD","LU1861219969.SGD","RVMD","BK4588","MDCO","LU1861214812.USD","BK4585","LU0124384867.USD","LU1861220033.SGD","BK4139","BK4141","IE00BD6J9T35.USD","IE00BZ199S13.USD","LU1854104046.USD","LU1854103824.USD","LU1978683503.SGD","LU1861215975.USD"],"gpt_icon":0},{"id":"2512132033","title":"TYK Medicines Concludes H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2512132033","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512132033?lang=en_us&edition=fundamental","pubTime":"2025-02-18 18:01","pubTimestamp":1739872897,"startTime":"0","endTime":"0","summary":"TYK Medicines  completed the conversion of 173,641,645 unlisted shares into Hong Kong shares on Tuesday, a same-day bourse filing said.The listing of the converted H shares will begin Wednesday, Feb. 19.The pharmaceutical products company applied for the H share full circulation in September 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","02410","BK1161"],"gpt_icon":0},{"id":"2512136425","title":"TYK Medicines Completes H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2512136425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512136425?lang=en_us&edition=fundamental","pubTime":"2025-02-18 16:40","pubTimestamp":1739868036,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. Class H ( ($HK:2410) ) just unveiled an announcement. TYK Medicines, Inc, a company incorporated in the People’s Republic of Ch...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-completes-h-share-full-circulation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tyk-medicines-completes-h-share-full-circulation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2512976281","title":"50 Years of Service: From Milkman's Son to Advancing Access to Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2512976281","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512976281?lang=en_us&edition=fundamental","pubTime":"2025-02-18 05:45","pubTimestamp":1739828700,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / February 17, 2025 / By Adelina Nedelcu. \"Observing my father's dedication to customer service taught me invaluable lessons about the importance of prompt service and meeting customer needs effectively. However, I aspired to be part of something larger, driven by a desire to make a meaningful impact on a broader scale,\" he said. \"I wanted to harness the energy of working with a team and apply the lessons I learned from my father - prompt service, attention to details and meeting people's needs. So, I decided to interview with one of Viatris' legacy companies and was hired the same day by the head of the administration department, the department where my career has started.\". \"Reflecting on my 50-year career, I am deeply inspired by our company's mission to empower people worldwide to live healthier lives at every stage of life. This mission has been the driving force behind my journey, fueling my passion and dedication,\" he said.As a second motivation","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/50-years-milkmans-son-advancing-214500825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","VTRS","MDCO","LU1839511570.USD","BK4588","BK4583","LU2087621335.USD"],"gpt_icon":0},{"id":"2512259319","title":"3D Medicines Inc. Reports Resolution in Civil Proceedings, Ensures Continued Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2512259319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512259319?lang=en_us&edition=fundamental","pubTime":"2025-02-17 23:07","pubTimestamp":1739804857,"startTime":"0","endTime":"0","summary":"3D Medicines, Inc. ( ($HK:1244) ) has issued an announcement. 3D Medicines Inc. has announced the lifting of a preservation order on bank accounts ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/3d-medicines-inc-reports-resolution-in-civil-proceedings-ensures-continued-operations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/3d-medicines-inc-reports-resolution-in-civil-proceedings-ensures-continued-operations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2511209006","title":"Steven Cohen's Strategic Acquisition in Praxis Precision Medicines Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2511209006","media":"GuruFocus","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511209006?lang=en_us&edition=fundamental","pubTime":"2025-02-15 14:27","pubTimestamp":1739600839,"startTime":"0","endTime":"0","summary":"On December 31, 2024, Steven Cohen (Trades, Portfolio), a renowned figure in the investment world, executed a significant transaction involving Praxis Precision Medicines Inc (PRAX, Financial). This t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2700392/steven-cohens-strategic-acquisition-in-praxis-precision-medicines-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["BK4139","PRAX","MDCO"],"gpt_icon":0},{"id":"2510371614","title":"TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access to Life-Changing Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2510371614","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510371614?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:02","pubTimestamp":1739365320,"startTime":"0","endTime":"0","summary":"Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/ -- TriNetX, a global leader in real-world data  and real-world evidence  solutions, has partnered with Fujitsu, a globalICT company and one of Japan's leadingelectronic health record  vendors, to form TriNetX Japan K.K. This groundbreaking joint venture aims to quickly create an environment where anonymized EHR data from Japanese patients can be used to optimize clinical trials, advance healthcare research, and accelerate drug development timelines.The initiative represents a significant step forward for integrating Japan into the global landscape of data-driven medicine and healthcare innovation. With its status as the third-largest pharmaceutical market worldwide, Japan offers unparalleled opportunities for clinical research and drug development. Additionally, Japan's rapidly aging populationprovides an ideal foundation for studying age-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/trinetx-fujitsu-launch-joint-venture-130200680.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trinetx-fujitsu-launch-joint-venture-130200680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCO","FJTSF","JYNT","BK4602","BK4134","BK4185","FJTSY"],"gpt_icon":0},{"id":"2510760378","title":"Market Chatter: China Healthcare Regulator Defends Efficacy of Local Generic Medicines in Hospital System","url":"https://stock-news.laohu8.com/highlight/detail?id=2510760378","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510760378?lang=en_us&edition=fundamental","pubTime":"2025-02-11 15:47","pubTimestamp":1739260024,"startTime":"0","endTime":"0","summary":"China's National Healthcare Security Administration said the generic drugs distributed through the country's public hospitals are as effective as original drugs, Reuters reported Sunday, citing state-","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4137","HCSG","MDCO"],"gpt_icon":0},{"id":"2510411827","title":"TYK Medicines Secures Hong Kong Exchange Listing Approval for Over 173.6 Million H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2510411827","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510411827?lang=en_us&edition=fundamental","pubTime":"2025-02-11 14:35","pubTimestamp":1739255748,"startTime":"0","endTime":"0","summary":"TYK Medicines  said the Listing Committee of the Stock Exchange of Hong Kong approved the listing of the company's 173,641,645 H shares on the exchange on Monday, a same-day bourse filing said.The said H shares are to be converted from the same number of unlisted shares held by 25 company shareholders. The exchange also granted permission to deal in the converted H shares to the company.The company had applied to the Exchange for the conversion and listing of the said shares on Sept. 13, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","02410","BK1161"],"gpt_icon":0},{"id":"2510484422","title":"3D Medicines Appoints Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2510484422","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510484422?lang=en_us&edition=fundamental","pubTime":"2025-02-11 10:39","pubTimestamp":1739241554,"startTime":"0","endTime":"0","summary":"3D Medicines  appointed Ding Gan as the chief commercial officer, according to a Monday filing with the Hong Kong bourse.Ding has more than 30 years of experience in the pharmaceutical and biotechnology industries, the filing added. He most recently served as served as the chief executive officer of Nicoya Therapeutics and Alternative Bio .Price : $2.98, Change: $-0.020, Percent Change: -0.67%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","MDCO","01244","BK4585","HKD","BK4023","BK4588","BK4526"],"gpt_icon":0},{"id":"2510865982","title":"3D Medicines Inc. Appoints New Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865982","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510865982?lang=en_us&edition=fundamental","pubTime":"2025-02-10 22:39","pubTimestamp":1739198371,"startTime":"0","endTime":"0","summary":"An update from 3D Medicines, Inc. ( ($HK:1244) ) is now available. 3D Medicines Inc. has announced the appointment of Mr. Ding Gan as the new Chief...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/3d-medicines-inc-appoints-new-chief-commercial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/3d-medicines-inc-appoints-new-chief-commercial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2509278479","title":"Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2509278479","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509278479?lang=en_us&edition=fundamental","pubTime":"2025-02-06 20:59","pubTimestamp":1738846799,"startTime":"0","endTime":"0","summary":"Eli Lilly&#39;s Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","MDCO"],"gpt_icon":1},{"id":"2509217050","title":"GSK PLC (GSK) Q4 2024 Earnings Call Highlights: Strong Specialty Medicines Drive Growth Amid ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2509217050","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509217050?lang=en_us&edition=fundamental","pubTime":"2025-02-06 15:05","pubTimestamp":1738825512,"startTime":"0","endTime":"0","summary":"Sales Growth: Increased by 8% to over GBP31 billion.Oncology Sales: Nearly doubled to more than GBP1.4 billion.HIV Sales Growth: Up 13% for the full year.Free Cash Flow: Improved to GBP3.5 billion, excluding Zantac payments.Share Buyback Program: Announced up to GBP2 billion over the next 18 months.2025 Sales Growth Guidance: Expected to increase between 3% and 5%.2025 Core Operating Profit and EPS Guidance: Expected to increase between 6% and 8%.GuruFocus has detected 4 Warning Signs with GSK.GSK PLC  reported an 8% increase in sales for 2024, reaching over GBP31 billion, driven by strong growth in specialty medicines.GSK PLC  adjusted its expectations for vaccine sales growth, anticipating a decrease in low single-digit percent in 2025.The company faces pricing and genericization pressures in its General Medicines portfolio, expecting sales to be broadly flat in 2025.Q: Within the mid-single-digit growth for HIV in 2025, are you anticipating much competitive impact from the launch of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gsk-plc-gsk-q4-2024-070512731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GSK","MDCO"],"gpt_icon":0},{"id":"2509323568","title":"Cencora Q1 Earnings: Revenue And EPS Beat On Strong Push From Obesity Drugs, Specialty Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2509323568","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509323568?lang=en_us&edition=fundamental","pubTime":"2025-02-06 00:09","pubTimestamp":1738771796,"startTime":"0","endTime":"0","summary":"Cencora posted Q1 sales of $81.5 billion, exceeding forecasts, with strong GLP-1 drug sales. Adjusted EPS beat estimates, and FY25 guidance was raised.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/general/health-care/25/02/43499747/cencora-q1-earnings-revenue-and-eps-beat-on-strong-push-from-obesity-drugs-specialty-medicines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCO","COR"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":153,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{}}}